IMNM
Price
$22.34
Change
-$1.90 (-7.84%)
Updated
Sep 24 closing price
Capitalization
2.75B
52 days until earnings call
Intraday BUY SELL Signals
ZVRA
Price
$11.26
Change
-$0.06 (-0.53%)
Updated
Sep 24 closing price
Capitalization
672.22M
47 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

IMNM vs ZVRA

IMNM vs ZVRA Comparison Chart in %
View a ticker or compare two or three
VS
IMNM vs. ZVRA commentary
Sep 25, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IMNM is a Buy and ZVRA is a StrongBuy.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS RATINGS
IMNM vs ZVRA: Fundamental Ratings
IMNM
ZVRA
OUTLOOK RATING
1..100
7791
VALUATION
overvalued / fair valued / undervalued
1..100
64
Fair valued
86
Overvalued
PROFIT vs RISK RATING
1..100
7875
SMR RATING
1..100
9829
PRICE GROWTH RATING
1..100
3847
P/E GROWTH RATING
1..100
10083
SEASONALITY SCORE
1..100
504

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IMNM's Valuation (64) in the null industry is in the same range as ZVRA (86). This means that IMNM’s stock grew similarly to ZVRA’s over the last 12 months.

ZVRA's Profit vs Risk Rating (75) in the null industry is in the same range as IMNM (78). This means that ZVRA’s stock grew similarly to IMNM’s over the last 12 months.

ZVRA's SMR Rating (29) in the null industry is significantly better than the same rating for IMNM (98). This means that ZVRA’s stock grew significantly faster than IMNM’s over the last 12 months.

IMNM's Price Growth Rating (38) in the null industry is in the same range as ZVRA (47). This means that IMNM’s stock grew similarly to ZVRA’s over the last 12 months.

ZVRA's P/E Growth Rating (83) in the null industry is in the same range as IMNM (100). This means that ZVRA’s stock grew similarly to IMNM’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IMNMZVRA
RSI
ODDS (%)
Bullish Trend 1 day ago
86%
N/A
Stochastic
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
82%
Momentum
ODDS (%)
Bearish Trend 1 day ago
78%
Bearish Trend 1 day ago
82%
MACD
ODDS (%)
Bearish Trend 1 day ago
80%
Bearish Trend 1 day ago
78%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
85%
Bearish Trend 1 day ago
76%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 1 day ago
76%
Advances
ODDS (%)
Bullish Trend 4 days ago
83%
Bullish Trend 9 days ago
82%
Declines
ODDS (%)
Bearish Trend 1 day ago
85%
Bearish Trend 1 day ago
74%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
90%
Bearish Trend 1 day ago
76%
Aroon
ODDS (%)
Bearish Trend 1 day ago
82%
Bullish Trend 1 day ago
73%
COMPARISON
Comparison
Sep 25, 2026
Stock price -- (IMNM: $22.34 vs. ZVRA: $11.26)
Brand notoriety: IMNM and ZVRA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IMNM: 243% vs. ZVRA: 49%
Market capitalization -- IMNM: $2.75B vs. ZVRA: $672.22M
IMNM [@Biotechnology] is valued at $2.75B. ZVRA’s [@Biotechnology] market capitalization is $672.22M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $130.87B. The average market capitalization across the [@Biotechnology] industry is $2.2B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IMNM’s FA Score shows that 0 FA rating(s) are green while ZVRA’s FA Score has 1 green FA rating(s).

  • IMNM’s FA Score: 0 green, 5 red.
  • ZVRA’s FA Score: 1 green, 4 red.
According to our system of comparison, ZVRA is a better buy in the long-term than IMNM.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IMNM’s TA Score shows that 4 TA indicator(s) are bullish while ZVRA’s TA Score has 4 bullish TA indicator(s).

  • IMNM’s TA Score: 4 bullish, 6 bearish.
  • ZVRA’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, ZVRA is a better buy in the short-term than IMNM.

Price Growth

IMNM (@Biotechnology) experienced а -6.64% price change this week, while ZVRA (@Biotechnology) price change was -4.90% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.44%. For the same industry, the average monthly price growth was -12.65%, and the average quarterly price growth was +6.78%.

Reported Earning Dates

IMNM is expected to report earnings on Nov 16, 2026.

ZVRA is expected to report earnings on Nov 11, 2026.

Industries' Descriptions

@Biotechnology (-3.44% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
IMNM
Daily Signal:
Gain/Loss:
ZVRA
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
JULM34.96N/A
+0.01%
FT Vest U.S. Equity Max Buffer ETF - July (JULM)
ORO21.35N/A
N/A
Arrow Valtoro ETF (ORO)
BKGI42.82-0.18
-0.42%
BNY Mellon Global Infrastructure Income ETF (BKGI)
TPZ20.31-0.31
-1.50%
Tortoise Electrification Infrastructure ETF (TPZ)
FXZ79.69-1.35
-1.66%
First Trust Materials AlphaDEX Fund (FXZ)